Safety of low-dose aprotinin in coronary artery bypass graft surgery: A single-centre investigation in 2436 patients in Germany

Drug Safety

Volumn 31, Issue 7, 2008, Pages 617-626

  Kluth, Mario ^a   Lueth, Jan U ^a   Zittermann, Armin ^a   Lanzenstiel, Markus ^a   Koerfer, Reiner ^a   Inoue, Kazuo ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Aprotinin, adverse reactions; Coronary bypass; Haemorrhage, prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; APROTININ; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOMIDATE; FENTANYL; HEPARIN; LORMETAZEPAM; MANNITOL; MORPHINE; NITRATE; PANCURONIUM BROMIDE; ROCURONIUM; SEVOFLURANE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; GASTROINTESTINAL DISEASE; HEART INFARCTION; HUMAN; INTERNAL MAMMARY ARTERY; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; PERIOPERATIVE PERIOD; POSTOPERATIVE CARE; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RISK ASSESSMENT; THORACOTOMY; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; APROTININ; CORONARY ARTERY BYPASS; FEMALE; HEMOSTATICS; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES;

EID: 45549085256     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200831070-00007     Document Type: Article

References (18)

1. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomised clinical trials. J Thorac Cardiovasc Surg 2004; 128: 442-8
2. Sedrakyan A, Wu A, Sedrakyan G, et al. Aprotinin use in thoracic aortic surgery: safety and outcomes. J Thorac Cardiovasc Surg 2006; 132: 909-17
3. Royston D, Levy JH, Fitch J, et al. Full-dose aprotinin use in coronary artery bypass graft surgery: an analysis of perioperative pharmacotherapy and patient outcomes. Anesth Analg 2006; 103: 1082-8
4. Kincaid EH, Ashburn DA, Hoyle JR, et al. Does the combination of aprotinin and angiotensin-converting enzyme inhibitor cause renal failure after cardiac surgery? Ann Thorac Surg 2005; 80: 1388-93
5. Karkouti K, Beattie WS, Dattilo KM, et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion- risk cardiac surgery. Transfusion 2006; 46: 327-38
6. Mangano DT, Tudor IC, Dietzel C. Multicenter study of Perioperative Ischemia Research Group and the Ischemia Research and Education Foundation: the risk associated with aprotinin in cardiac surgery. New Engl J Med 2006; 354: 353-65
7. Mangano DT, Miao Y, Vuylsteke A, et al. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA 2007; 297: 471-9
8. Ferguson TB. Aprotinin: are there lessons learned? JAMA 2007; 297: 527-9
9. Coleman CI, Rigali VT, Hammond J, et al. Evaluating the safety implications of aprotinin use: the retrospective evaluation of aprotinin in Cardio Thoracic Surgery (REACTS). J Thorac Cardiovasc Surg 2007; 133: 1547-52
10. Schönberger JP, Everts PA, Ercan H, et al. Low-dose aprotinin in internal mammary artery bypass operations contributes to important blood saving. Ann Thorac Surg 1992; 54: 1172-6
11. Santamaria A, Mateo J, Oliver A, et al. The effect of two different doses of aprotinin on hemostasis in cardiopulmonary bypass surgery: similar transfusion requirements and blood loss. Haematolgica 2000; 85: 1277-84
12. Liu B, Belboul A, Larsson S, et al. Factors influencing haemostasis and blood transfusion in cardiac surgery. Perfusion 1996; 11: 131-43
13. Brown JR, Nancy JO, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007; 115: 2801-13
14. Henry DA, Carless PA, Moxey AJ, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007; Oct 17: CD001886
15. Furnary AP, Wu Y, Hiratzka LF, et al. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 2007; 116: 1127-33
16. Hiatt WR. Observational studies of drug safety: aprotinin and the absence of transparency. New Engl J Med 2006; 355: 2171-3
17. Gummert JF, Funkat A, Krian A. Cardiac surgery in Germany during 2004: a report on behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg 2005; 53: 391-9
18. Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008; 358: 2319-31